The effect of topical ketanserin on intraocular pressure (IOP) in norm
otensive and hypertensive eyes was evaluated. The study was performed
on 10 healthy volunteers and 10 glaucomatous patients. Systolic arteri
al blood pressure (SBP), diastolic arterial blood pressure (DBP), hear
t rate (HR), IOP, tonographic outflow facility, pupil diameter, cornea
l thickness, and tear secretion were recorded at baseline and at 1 hou
r intervals for 12 hours after topical administration of 0-5% ketanser
in or placebo, given in a randomised, double masked, crossover fashion
. The alternative treatment was given 1 week later. In all subjects ke
tanserin significantly lowered IOP, while no variations in SBP, DBP, H
R, pupil diameter, corneal thickness and tear secretion were found. Wh
en subjects received placebo no significant variations of IOP occurred
. Total outflow facility, measured by conventional tonography, increas
ed significantly after drug administration in all subjects. Ketanserin
is effective up to 6 hours in control subjects and 9 hours in glaucom
atous patients. The placebo did not induce any change in this componen
t of the aqueous humour dynamic in normal or in glaucomatous eyes. The
findings indicate that topical ketanserin might be added to the list
of antiglaucomatous agents.